Table 2. Detailed information of the 4 patients who maintained PR or SD for at least 6 months with pembrolizumab.

Sex	Age	Subtype	ECOG score	LDH	Treatment time	PD-L1	Treatment group	Therapeutic response	Time to progression
M	52	ASPS	2	0	Second-line	NA	Pembrolizumab alone	PR	Not reached
F	45	UPS	0	0	Second-line	NA	Combined AD	PR	Not reached
M	79	ESCS	2	1	Second-line	Positive	Combined lenvatinib	PR	13 months
M	47	AS	1	0	First-line	Positive	Combined AD	CR	Not reached

ECOG, Eastern Cooperative Oncology Group; PR, partial response; CR, complete response; SD, stable disease; PD-L1, programmed cell death-ligand 1; LDH, lactate dehydrogenase; ASPS, alveolar soft part sarcoma; UPS, undifferentiated pleomorphic sarcoma; ESCS, exoskeletal chondrosarcoma; AS, angiosarcoma; NA, not available; AD, anthracycline and dacarbazine.